Reiko Matsui

Dr. Reiko Matsui


Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 September 2019 in Scientific Reports
Verified
Journal Article
Open access
PDF file
TKToyokazu Kimura
Toyokazu Kimura
BFBeatriz Ferran
Beatriz Ferran
YTYuko Tsukahara
Yuko Tsukahara
QSQifan Shang
Qifan Shang
SDSuveer Desai
Suveer Desai
MBMarkus Michael Bachschmid
Markus Michael Bachschmid
Delivering and expressing a gene of interest in cells or living animals has become a pivotal technique in biomedical research and gene therapy. Among viral delivery systems, adeno-associated viruses (AAVs) are relatively safe and demonstrate high gene transfer efficiency, low immunogenicity, stable long-term expression, and selective tissue tropism. Combined with modern gene technologies, such as cell-specific promoters, the Cre/lox system, and genome editing, AAVs represent a practical, rapid, and economical alternative to conditional knockout and transgenic mouse models. However, major obstacles remain for widespread AAV utilization, such as impractical purification strategies and low viral quantities. Here, we report an improved protocol to produce serotype-independent purified AAVs economically. Using a helper-free AAV system, we purified AAVs from HEK293T cell lysates and medium by polyethylene glycol precipitation with subsequent aqueous two-phase partitioning. Furthermore, we then implemented an iodixanol gradient purification, which resulted in preparations with purities adequate for in vivo use. Of note, we achieved titers of 1010–1011 viral genome copies per µl with a typical production volume of up to 1 ml while requiring five times less than the usual number of HEK293T cells used in standard protocols. For proof of concept, we verified in vivo transduction via Western blot, qPCR, luminescence, and immunohistochemistry. AAVs coding for glutaredoxin-1 (Glrx) shRNA successfully inhibited Glrx expression by ~66% in the liver and skeletal muscle. Our study provides an improved protocol for a more economical and efficient purified AAV preparation.

20 October 2011 in Annals of Medicine
Verified
Journal Article
Open access
PDF file
MBMarkus M. Bachschmid
Markus M. Bachschmid
SSStefan Schildknecht
Stefan Schildknecht
RMReiko Matsui
Reiko Matsui
RZRebecca Zee
Rebecca Zee
DHDagmar Haeussler
Dagmar Haeussler
BLBernd van der Loo
Bernd van der Loo
Characteristic morphological and molecular alterations such as vessel wall thickening and reduction of nitric oxide occur in the aging vasculature leading to the gradual loss of vascular homeostasis. Consequently, the risk of developing acute and chronic cardiovascular diseases increases with age. Current research of the underlying molecular mechanisms of endothelial function demonstrates a duality of reactive oxygen and nitrogen species in contributing to vascular homeostasis or leading to detrimental effects when formed in excess. Furthermore, changes in function and redox status of vascular smooth muscle cells contribute to age-related vascular remodeling. The age-dependent increase in free radical formation causes deterioration of the nitric oxide signaling cascade, alters and activates prostaglandin metabolism, and promotes novel oxidative posttranslational protein modifications that interfere with vascular and cell signaling pathways. As a result, vascular dysfunction manifests. Compensatory mechanisms are initially activated to cope with age-induced oxidative stress, but become futile, which results in irreversible oxidative modifications of biological macromolecules. These findings support the ‘free radical theory of aging’ but also show that reactive oxygen and nitrogen species are essential signaling molecules, regulating vascular homeostasis.

20 February 2020 in Antioxidants & Redox Signaling
Verified
Journal Article
Closed access
RMReiko Matsui
Reiko Matsui
BFBeatriz Ferran
Beatriz Ferran
AOAlbin Oh
Albin Oh
DCDominique Croteau
Dominique Croteau
DSDi Shao
Di Shao
MBMarkus Michael Bachschmid
Markus Michael Bachschmid
Significance: Over the past several years, oxidative post-translational modifications of protein cysteines have been recognized for their critical roles in physiology and pathophysiology. Cells have harnessed thiol modifications involving both oxidative and reductive steps for signaling and protein processing. One of these stages requires oxidation of cysteine to sulfenic acid, followed by two reduction reactions. First, glutathione (reduced glutathione [GSH]) forms a S -glutathionylated protein, and second, enzymatic or chemical reduction removes the modification. Under physiological conditions, these steps confer redox signaling and protect cysteines from irreversible oxidation. However, oxidative stress can overwhelm protein S -glutathionylation and irreversibly modify cysteine residues, disrupting redox signaling. Recent Advances: The latest studies of glutaredoxin-1 ( Glrx ) transgenic or knockout mice demonstrate important distinct roles of Glrx in a variety of pathologies. Endogenous Glrx is essential to maintain normal hepatic lipid homeostasis and prevent fatty liver disease. Further, in vivo deletion of Glrx protects lungs from inflammation and bacterial pneumonia-induced damage, attenuates angiotensin II-induced cardiovascular hypertrophy, and improves ischemic limb vascularization. Meanwhile, exogenous Glrx administration can reverse pathological lung fibrosis. Critical Issues: Glutaredoxins mainly catalyze the removal of protein-bound GSH and help maintain protein thiols in a highly reduced state without exerting direct antioxidant properties. Conversely, glutathione S -transferase (GST), peroxiredoxins, and occasionally glutaredoxins can also catalyze protein S -glutathionylation, thus promoting a dynamic redox environment. Future Directions: Although S -glutathionylation modifies many proteins, these studies suggest that S -glutathionylation and Glrx regulate specific pathways in vivo , and they implicate Glrx as a potential novel therapeutic target to treat diverse disease conditions. Antioxid. Redox Signal . 32, 677–700.

12 July 2005 in Circulation
Verified
Journal Article
Closed access
PDF file
RMReiko Matsui
Reiko Matsui
SXShanqin Xu
Shanqin Xu
KMKarlene A. Maitland
Karlene A. Maitland
AHAntoinette Hayes
Antoinette Hayes
JLJane A. Leopold
Jane A. Leopold
RCRichard A. Cohen
Richard A. Cohen
Background— Glucose-6-phosphate dehydrogenase (G6PD) regulates production of the reduced form of NADPH through the pentose phosphate pathway. G6PD may therefore affect superoxide anion production via vascular NADPH oxidase, which is key in mediating the vascular response to angiotensin II (Ang II). We determined the hypertensive and vascular hypertrophic response to Ang II in G6PD-deficient mice. Methods and Results— Ang II (0.7 mg/kg per day) was infused via subcutaneous osmotic pumps for 6 days in male hemizygote G6PD mutant (G6PD mut ) and wild-type (WT) C3H mice. (1) Compared with WT, G6PD mut mouse aorta had 10% to 20% of G6PD activity and 50% less NADPH. (2) Basal systolic blood pressure was not significantly different in G6PD mut mice (WT 88±4 mm Hg versus G6PD mut 95±4 mm Hg), but Ang II increased blood pressure to a lower level in G6PD mut mice (WT 139±4 mm Hg versus G6PD mut 123±5 mm Hg; P <0.05). (3) Ang II increased aortic medial thickness less in G6PD mut mice (WT 71±2 μm versus G6PD mut 62±1 μm; P <0.01). (4) 3- o -Nitrotyrosine staining and dihydroethidium oxidation in the aorta was increased by Ang II less in G6PD mut mice. (5) Smooth muscle cells isolated from G6PD mut mice showed less Ang II–induced phosphorylation of Akt and p42/44 ERK. Conclusions— G6PD deficiency may reduce vascular superoxide anion production by limiting production of the substrate for NADPH oxidase, thereby inhibiting oxidant-mediated Ang II–induced signaling pathways that contribute to hypertension and smooth muscle hypertrophy.

31 May 2002 in Circulation Research
Verified
Journal Article
Closed access
PDF file
TATakeshi Adachi
Takeshi Adachi
RMReiko Matsui
Reiko Matsui
SXShanqin Xu
Shanqin Xu
MKMichael Kirber
Michael Kirber
HLHarold L. Lazar
Harold L. Lazar
RCRichard A. Cohen
Richard A. Cohen
Antioxidants improve endothelial function in hypercholesterolemia (HC); however, whether this includes improvement of the vascular smooth muscle response to NO is unknown. NO relaxes arteries, in part, by stimulating Ca 2+ uptake via sarco/endoplasmic reticulum Ca 2+ -ATPase (SERCA) in aortic smooth muscle, and HC impairs SERCA function and the response to NO. HC induces oxidative stress, which could impair SERCA function. To study the effect of antioxidants, which are known to improve endothelium-dependent relaxation in HC, smooth muscle SERCA activity and NO-induced relaxation were studied in rabbits fed normal chow or a 0.5% cholesterol diet for 13 weeks. The antioxidant t -butylhydroxytoluene (BHT, 1%) was mixed with the HC diet in the last 3 weeks. HC impaired acetylcholine- and NO-induced relaxation, and these were restored by BHT. After inhibiting SERCA with thapsigargin, no difference existed in NO-induced relaxation among the three groups. Reduced aortic SERCA activity in HC was restored by BHT without changing SERCA protein expression. 3-Nitrotyrosine was notably increased in the media of the HC aorta, where it colocalized with SERCA. Tyrosine-nitrated SERCA protein was immunoprecipitated in the aortas of HC rabbits, where it was decreased by BHT, and it was also detected in the aortas of atherosclerotic humans. Thus, the antioxidant reverses impaired smooth muscle SERCA function in HC, and this is correlated with the improved relaxation to NO. These beneficial effects may depend on reducing the direct effects on SERCA of reactive oxygen species that are augmented in HC.

9 May 2016 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
YWYosuke Watanabe
Yosuke Watanabe
CMColin Edward Murdoch
Colin Edward Murdoch
SSSoichi Sano
Soichi Sano
YIYasuo Ido
Yasuo Ido
MBMarkus M. Bachschmid
Markus M. Bachschmid
RMReiko Matsui
Reiko Matsui
Significance: Glutathione (GSH)-protein adducts are oxidative posttranslational modifications that are reversed by glutaredoxin-1 (Glrx). We show that ischemia-induced oxidants promote revascularization through GSH adducts on hypoxia-inducible factor (HIF)-1α, an angiogenic transcriptional factor. GSH adducts on Cys 520 stabilize HIF-1α protein, and depletion of Glrx stabilizes HIF-1α in vitro and increases angiogenic gene expression. Glrx ablation in vivo increases GSH adducts in ischemic muscles after femoral artery ligation in mice and improves blood flow recovery associated with increased HIF-1α and VEGF expression. Thus, increased GSH-protein adducts on HIF-1α in ischemic limbs are beneficial in promoting angiogenesis. Our data indicate HIF-1α is a novel in vivo target of Glrx, and inhibition of Glrx is a potential therapeutic strategy to improve ischemic limb revascularization.